Pharming Group N.V. today announces that the European Commission has granted orphan drug designation for leniolisib for the treatment of activated phosphoinositide 3-kinase delta syndrome (APDS), based on a positive opinion from the Committee for Orphan Medicinal Products (COMP) of the European Medicine Agency (EMA).

On the 29th of October at 19:00 Pharming’s CEO, Sijmen de Vries will discuss the recently published Q3 2020 financial results, provide a business update and insight into market developments. Submit your questions in advance to investor@pharming.com

Pharming Group N.V. today announces the publication of data in the peer-reviewed journal, Frontiers in Immunology, from a compassionate use programme of five patients with confirmed COVID-19 (SARS-CoV-2) infections hospitalised with related severe pneumonia that were treated with RUCONEST® (recombinant human C1 inhibitor, conestat alfa) at the University Hospital Basel, Switzerland.

Pharming Group N.V. announces that the first patient has been enrolled in a randomized, controlled, investigator-initiated clinical trial in up to 150 patients for the treatment with RUCONEST® (recombinant human C1 inhibitor) of patients with confirmed COVID-19 (SARS-CoV-2) infections hospitalised with related severe pneumonia at the University Hospital Basel in Basel, Switzerland.

Pharming Group N.V. presents its (unaudited) financial report for the six months ended 30 June 2020.

Pharming’s CEO Sijmen de Vries and Leon Melens look back at the first half year and the recently published half year financial results.

Pharming Group N.V. announces that at its Annual General Meeting of shareholders (AGM), held today, the proposals related to remuneration were withdrawn and all other proposals were approved.

Pharming Group N.V. announces the nomination of Barbara Yanni and Mark Pykett to its Board of Supervisory Directors. An Extraordinary General Meeting of Shareholders is expected to be convened later this year for their official appointment. Until that moment, Barbara Yanni and Mark Pykett will hold an observational role within Pharming’s Board of Supervisory Directors.

Pharming Group N.V. today supports “hae-day :-)”, the global awareness day for hereditary angioedema (HAE), a rare life-threatening condition.

Pharming Group N.V. holds it 2020 Annual General Meeting (AGM) on 20 May 2020 at 14:00 CET.